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Abstract
Background Women with early-stage breast cancer face a multitude
of decisions. The quality of a decision can be measured by the extent
to which the treatment reflects what is most important to an
informed patient. Reliable and valid measures of patients knowl-
edge and their goals and concerns related to breast cancer treatments
are needed to assess the decision quality.
Objective To identify a set of key facts and goals relevant to each of
three breast cancer treatment decisions (surgery, reconstruction and
adjuvant chemotherapy and hormone therapy) and to evaluate the
validity of the methods used to identify them.
Methods Candidate facts and goals were chosen based on evidence
review and qualitative studies with breast cancer patients and
providers. Cross-sectional surveys of patients and providers were
conducted for each decision. The accuracy, importance and com-
pleteness of the items were examined.
Results Thirty-eight facts (11–14 per decision) and 27 goals (8–10
per decision) were identified. An average of 17 patients and 21
providers responded to each survey. The sets of facts were accurate
and complete for all three decisions. The sets of goals and concerns
were important for surgery and reconstruction, but not chemother-
apy ⁄hormone therapy. Patients and providers disagreed about the
relative importance of several key facts and goals.
Conclusions Overall, breast cancer patients and providers found the
sets of facts and goals accurate, important and complete for three
treatment decisions. Because patients and providers perspectives
are different, it is vital that instrument development should include
items reflecting both views.
doi: 10.1111/j.1369-7625.2010.00600.x
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Introduction
A diagnosis of early-stage breast cancer sets off a
series of preference-sensitive treatment deci-
sions, including: (i) initial surgical choice
between mastectomy and breast-conserving
surgery; (ii) whether to have breast reconstruc-
tion if mastectomy is chosen; and (iii) whether or
not to have adjuvant chemotherapy, hormone
therapy (CHT) or both. Clinical guidelines and
quality measures recognize that there is not one
right answer for any of these decisions.1–3
Rather, consensus is growing that a high-quality
decision for such preference-sensitive conditions
is one that reflects the considered preferences of
well-informed patients.4,5 In order to evaluate
the quality of preference-sensitive decisions,
instruments are needed that assess whether the
patient is informed of the choices, understands
the likelihood of positive and negative outcomes
of each decision, and whether the treatment she
gets reflects what is most important to her.
Although a number of studies have examined
the degree to which breast cancer patients are
informed about their treatment options, few
have used measures of knowledge with proven
reliability and validity. Four studies have
reported knowledge for the surgical decision,6–10
one has assessed knowledge of reconstruction,10
two have assessed knowledge of chemother-
apy11,12 and none has assessed knowledge of
hormone therapies. On close inspection of these
studies measures, only one was a previously
validated knowledge instrument. It was vali-
dated in 1990 and is outdated for our purposes.6
The other instruments were created specifically
for their particular studies. Two studies
described how the items were generated, and
both were developed using medical expert input
without patient input.6–9 None of the studies
reported reliability or validity of the knowledge
instruments for the study sample.
Studies of patients preferences about breast
cancer treatments have also been limited by the
quality of measures. Several cross-sectional
studies have identified patient concerns associ-
ated with choice of surgical treatment.13–17 Two
studies have examined patients preferences and
their association with decisions about recon-
struction.18,19 Only one of these studies used
previously validated instruments and reported
information on the reliability or validity of the
data.18 The others developed the items specifi-
cally for the study and did not report on reli-
ability or validity. Although the issues explored
by these studies had significant conceptual
overlap, the wording and scaling tasks differed.
Studies of decision making about adjuvant
chemotherapy and hormonal therapy (CHT)
have taken the approach of measuring howmuch
benefit a patient would need to gain in order to
make the side effects of treatment worthwhile.20–
24 Most studies have used structured interviews
and time-trade-off exercises to estimate the
required level of benefits. Although the impor-
tance of weighing the benefits and harms seems
obvious, the benefits and harms used in the
exercises varied. Furthermore, all of the patients
in these studies had taken the treatment (che-
motherapy and ⁄or hormonal therapy). How well
these approaches would work in patients actually
facing CHT decisions is not known.
A more transparent and rigorous process is
needed to identify the key pieces of information
that patients should understand and the salient
issues that may determine their preference for
one treatment over another. The authors and
their colleagues have designed such a process for
the development of decision quality instruments
(DQIs) specific to common clinical decisions,
including breast cancer treatment decisions.25
The development process for the instruments is
summarized in the methods and Table 1. The
first step in developing the instruments is to
generate a core set of facts that is essential for
patients to understand before making a decision,
as well as a core set of salient goals and concerns
that lead patients to prefer one treatment over
another.
Here, we report the results of cross-sectional
surveys of breast cancer survivors and providers
for three decisions: surgery for early-stage breast
cancer; breast reconstruction, and adjuvant
chemotherapy and hormone therapy for early-
stage breast cancer. The purpose of the surveys
was to assess the accuracy, importance and
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completeness of the set of candidate facts and
goals. A secondary aim was to determine
whether or not a small, core set of information
and goals, which providers and patients would
both agree is essential, exists.
Methods
Purpose and item development
The rationale for the DQIs,5 conceptual under-
pinnings of the approach26 and pilot results25,27
have been described. The underlying conceptual
framework builds on the systems approach to
decision making described by Mulley in
1989.28,29 This framework attempts to bridge the
tension between normative (or rational theories
of decision making, which promote fully
informed choices that maximize expected utility)
and behavioural decision theories (which
describe the heuristics, biases and traps that
people often use when actually making deci-
sions).30 For example, it recognizes that people
have limited cognitive capacity and limited
resources and will never reach the normative
ideal. In addition, it recognizes that factors other
than utilities for health states may appropriately
influence choices. We refer to these factors more
generally as goals and concerns in order to
distinguish them from the formal utilities of
decision analysis. We specifically do not use
preferences to describe these items, as the term
has many different meanings, including pre-
ferred treatment, preferred role in decisions,
time and risk preferences, and preferences for
specific outcomes and attributes.
The DQIs are designed to measure the
extent to which treatments reflect informed
patients goals and concerns. The instruments
are composed of a set of decision-specific
knowledge questions and a set of subjective
assessments of patients goals and concerns.
The facts cover the following five domains:
Disease (such as the prevalence, lethality and
natural history), Choices (such as a description
of the treatment options and whats involved
with each), Benefits of the choices (such as
survival, symptom relief, likelihood of out-
comes), Harms of the choices (such as serious
and permanent problems, temporary and
Table 1 Development process for decision quality instruments
Phase of instrument development Development steps
1. Identification of key facts and goals Review clinical evidence and decision-making literature
Review literature on patient perspective, and
conduct focus groups and interviews with
patients and providers
Draft candidate facts and goals across key
domains and review with medical experts and
decision-making experts
Conduct cross-sectional surveys of patients and
providers to assess accuracy, importance, and
completeness of candidate facts and goals
2. Drafting of questions Draft survey items for key facts and goals
Conduct cognitive testing of survey items with patients
Revise items based on literacy review by expert
Revise items based on medical review by providers
Field test with patients to assess reliability and validity
Refine instruments based on field test results
3. Validation of instrument Evaluate performance in diverse samples of patients
Conduct broad-scale review by providers
Review items for accuracy and completeness on
annual basis, including patient and provider input as needed
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common problems, the likelihood of problems)
and the Decision situation (such as the urgency
to treat, patients role in the decision, recog-
nition of decision).
The goals and concerns include good and bad
health outcomes and other factors that patients
reported were critical to their decisions, phrased
in their language. The goals cover the following
categories: Benefits (such as symptom relief due
to a treatment), Harms (such as long-term,
adverse health states possible after a treatment,
or temporary adverse health state during or
shortly after a treatment), Other attitudes about
non-health states (e.g. time spent getting treat-
ment or in recovery, costs), Holistic attitudes
towards treatment or approach to treatment
(e.g. always want to do as much as possible,
avoiding medication) and Influence of others
(e.g. following doctors or spouses recommen-
dation).
The candidate facts and goals were generated
by patients, medical experts and decision-mak-
ing experts, and were based on reviews of the
clinical evidence and qualitative studies of breast




For each decision, a convenience sample of
breast cancer providers, including breast cancer
nurses, medical oncologists, surgical oncologists,
general surgeons and plastic surgeons, was
identified. Providers were identified through
colleagues and through academic and commu-
nity websites. Eligible providers were mailed the
survey and a $10 incentive. Non-responders
were sent a reminder and then another copy of
the survey after 4 weeks. Responders received an
additional $40 for completing the survey.
Patients
A convenience sample of patients was re-
cruited through a combination of newspaper
advertisements, flyers, registries, providers and
patient support groups in the areas around
Dartmouth Hitchcock Medical Center and the
University of Massachusetts Boston. Respon-
dents were screened by phone. Those who were
older than 21, with a history of early-stage
breast cancer diagnosed within 5 years prior to
contact, and who could speak and read English
were eligible. We limited the time from diag-
nosis to 5 years so that participants would have
faced the same treatment options available to
current patients. Because we were developing
instruments, we felt that enrolling newly-diag-
nosed patients would pose unjustified burden at
a time of great stress. In addition, because
patients who are still making decisions would
not have enough perspective to reflect on the
information they needed, we sought some
hindsight to guide the rating of facts and goals.
For the reconstruction survey, participants must
have had a mastectomy. Although we were
aware that knowledge about breast reconstruc-
tion could affect decisions between mastectomy
and breast conservation, we chose to exclude
women who had breast conservation from the
reconstruction survey, to maximize the rele-
vance of responses in our small sample. Each
eligible patient was mailed a survey for one
decision. Non-responders were sent a reminder
and then a second copy of the survey again after
4 weeks. Responders were given $10–25 for
completing the survey.
Data collection
Participants rated the importance of each fact
and goal on a four-point scale (1 = Not
Important, 2 = Somewhat Important, 3 =
Very Important, 4 = Extremely Important),
selected their top three most important facts and
goals, and added any additional facts and goals
and concerns that they thought were salient to
the decision.
Analysis
The primary objective of analysis was to assess
the degree to which the set of candidate facts
and goals was accurate, important and com-
plete. Secondary analyses examined the amount
of agreement between patients and providers
regarding the importance of each candidates
fact and goal.
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Accuracy
Participating providers were asked to identify
any inaccuracies in the candidate facts.
Although we did not specifically ask patients to
identify inaccuracies, we considered any inac-
curacies that they noted. If anyone (regardless of
specialty) raised a concern about the accuracy of
a fact, we sought evidence to clarify the concern.
Here, published peer-reviewed studies trumped
personal experience – so, for example, if a sur-
geon said their complication rate was lower but
did not have published evidence of their rates to
support the claim, we did not consider the fact
inaccurate. Adding a fact to the list required
more than one person to mention it, thus
requiring it to be not a unique concern, but one
that is shared or more widely recognized. An
expert in breast cancer evidence and clinical care
also evaluated any suggested inaccuracies to
determine whether or not the clinical evidence
supported the suggested change. Corresponding
changes were then made to the next version of
the DQI, to be used in subsequent testing. If one
or fewer changes were made to items, the set of
facts was considered accurate. The set of can-
didate goals was not assessed for accuracy
because they are subjective.
Importance
A weighted median was calculated for patients
and providers ratings of importance for each
candidates fact and goal, for each condition.
The weighted median gave equal weight to the
patient sample and the provider sample. All
items that had a weighted median >2 were
considered important. If an item had a weighted
median of 2 or less, and fewer than 10% of
patients and fewer than 10% of providers placed
the item in their top three, then the item was
considered a candidate for deletion. A set of
facts and goals for a given condition was con-
sidered important if two or fewer facts and two
or fewer goals were candidates for deletion.
Completeness
Additional facts and goals provided by patient
or provider participants in response to the open-
ended questions were evaluated to determine if
they were accurate and relevant, and if they
added new content to the existing set of items.
Accurate, relevant and additional suggestions
were added to the candidate list only if two or
more respondents (patients or providers or both)
offered the same or similar suggestions, indicat-
ing wider importance. A set of facts and goals
for a given condition was considered complete
if two or fewer facts and two or fewer goals were
added to the candidate list.
Agreement between patients and providers
First, for each candidates fact and goal, we
determined the percentage of times the fact or
goal was reported, by patients and providers
respectively, to be among the three most
important facts or goals. Based on these results,
we identified the three most commonly selected
facts and goals among patients and among
providers to see how much overlap there was in
the top three ranked items. Then, for each item,
the percentage of patients who placed the item in
their top three was compared with the percent-
age of providers who placed the item in their top
three. The asymptotic 95% confidence interval
(CI) around the difference between the patient
and provider percentages was calculated for
each item. CIs excluding 0 were considered
evidence of statistically significant differences
in importance ratings between patients and
providers.
Results
Response rates and sample
Across the three decisions, the patients response
rate was 79% and the providers response rate
was 77%. Tables 2a and 2b describe the demo-
graphics of the patient and provider samples.
Fifteen providers, including six surgeons, com-
pleted the surgery survey. Twenty providers,
including 11 plastic surgeons, completed the
reconstruction survey. Twenty-seven providers,
including 11 medical oncologists, completed the
CHT survey. Four providers completed two
surveys (surgery and reconstruction). Each
patient completed only one survey.
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Performance of the facts
Accuracy
Providers had very few comments on the items
(two for surgery, three for CHT and four for
reconstruction) and did not identify significant
inaccuracies. For the surgery item Radiation
involves treatments five days a week for 5 to
6 weeks, one provider noted that partial breast
irradiation techniques do not take several weeks.
As a result, we added a qualifier traditional to
the description of radiation. For the recon-
struction item, Prosthesis can provide a natural
look in clothes, one provider did not agree with
this statement and another remarked that it
depended on the clothes. As a result, we added a
qualifier most to clothes. None of the other
comments resulted in changes to the items.
Patients did not note any inaccuracies. Overall,
the set of facts for each of the three decisions
was considered accurate.
Importance
The overall median importance rating of the
facts was three (range 3–4). As none of the
items had a median importance score of 2 or
less, no facts were candidates for deletion for
any decisions. Overall, both patients and
providers considered each set of facts impor-
tant.
Completeness
Respondents wrote in 21 comments on the sur-
veys (four for surgery, nine for CHT and eight
for reconstruction). Only one resulted in an
additional fact – that reconstruction does not









(% HS or less)
Mean years
since dx
Surgery 14 64 (40–83) 100 43% mast 36 1.7
Reconstruction 21 50 (35–69) 92 85% (11 ⁄ 13) recon* 15 2.7
Chemotherapy ⁄
hormone therapy**





dx, diagnosis; HS, high school; mast, mastectomy; recon, surgical breast reconstruction; CH, chemotherapy; HT, hormone therapy; none, no
systemic therapy.
*For reconstruction, treatment data were available for 13 of the 21 patients.
**For CHT, demographic data were available for 13 of the 17 patients.














Surgery 15 49 (30–59) 27 24 (5–30) 30 55% physician
45% surgery*




27 47 (30–65) 27 16 (2–30) 200 60% physician
67% medical oncology*
*Percentage of the physicians.
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interfere with cancer surveillance or impact the
likelihood of recurrence. Some suggestions were
already covered by the existing items. For
example, two patients suggested that the trauma
and after-effects of flaps needed more emphasis.
We added additional details to the existing item
Implants require less extensive surgery than
flaps. Other suggestions were not relevant to the
primary purpose of the instruments. For exam-
ple, both patients and providers wrote in that
they wanted more information on aromatase
inhibitors in the CHT facts. The DQI is intended
for use at the level of selecting types of medi-
cations (i.e. chemotherapy, hormone therapy or
no medication), rather than specific agents, so
we did not add specific items on aromatase
inhibitors. None of the other suggestions was
mentioned by more than one respondent.
Overall, the set of facts for each decision was
considered complete.
Performance of the goals
Importance
For surgery, the weighted median of the
importance ratings ranged from 2 to 4, and no
items were candidates for deletion. For recon-
struction, the weighted median of the impor-
tance ratings ranged from 2 to 3, and no items
were candidates for deletion. For CHT, the
weighted median of the importance ratings
ranged from 2 to 4. Three items, avoid short-
term side effects of chemotherapy, maintain
fertility and do what your doctor thinks is
best were candidates for deletion. The item on
the short-term side effects of chemotherapy
was deleted, but the other two items were
kept. Although fertility is only relevant for
younger women (a small minority of breast
cancer patients), we decided that the issue
was significant enough for those women to
warrant keeping it. The item about the
doctors recommendation is a theme across
many different conditions and was also kept,
but as a preference about participation in
decisions and not as a goal. The sets of goals for
surgery and for reconstruction were considered
important.
Completeness
For surgery, providers suggested one additional
goal, and patients suggested four. The items
were fairly general (e.g. the experience of the
doctor and the hospitals MRSA infection rate)
and would not necessarily lead a woman to
choose one surgery over another. None was
mentioned by more than one respondent. For
reconstruction, providers wrote in four goals
and patients wrote in two. The one item that was
mentioned by two respondents, wanting to
avoid complications of surgery, was added to
the set of goals.
For CHT, providers added one goal, and
patients added six. Three patients added the goal
of balancing benefits and side effects of adjuvant
therapy. Two providers wrote in consideration
of the absolute risks for an individual patient.
Because 7 of the 10 goals already covered the
benefits or side effects of adjuvant therapy,
including asking patients about knowledge of
the absolute benefit of therapy, we considered
these additions to be redundant. No additional
goals were added. Overall, the sets of goals and
concerns for each decision were considered
complete.
Agreement among and between providers and
patients
Surgery facts
Patients and providers ranked several different
facts as being among the three most impor-
tant, with some overlap among the facts most
often selected by both types of respondents
(see Table 3a). Significantly more providers
than patients (53% vs. 14%, 95% CI of the
difference: )70, )8) felt that the fact for most
women with early-stage breast cancer, waiting
4 weeks to make a treatment decision would
not affect their chances of survival was
important.
Surgery goals
Patients and providers almost unanimously felt
that minimizing the chance of recurrence was
the key goal for this decision. This was the
only item for all surveys that reached greater
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than 90% for both groups. Patients were sig-
nificantly less likely than providers to consider
keep your breast as a top goal when choosing
surgery (7% vs. 71%, 95% CI of the differ-
ence: )92, )37). Patients were significantly
more likely than providers to select do what
your doctor thinks is best in their top three
goals (86% vs. 14%, 95% CI of the difference:
)97, )46).
Reconstruction facts
Only one reconstruction fact, about 1 ⁄3 of
patients who have reconstruction will have a
major complication, was most frequently
ranked in the top three by both providers and
patients (Table 3b). Otherwise, patients and
providers appeared to focus on different
aspects of the decision. Providers were more
concerned about the impact of radiation on







95% CI of the
difference
Surgery fact*
Patients who have lumpectomy live as long as those who
have mastectomy
43 73 )65 to 4
Waiting 4 weeks to make a treatment decision does not
affect survival
14 53 )70 to )8
The chance of cancer coming back in the treated breast is
slightly higher after lumpectomy and radiation
36 27 )25 to 43
If 100 women have lumpectomy and radiation, 5–15 will
have cancer come back in 10 years
29 27 )31 to 35
Most women are candidates for both types of treatment and
have a choice
36 27 )25 to 43
Some who have lumpectomy will need more than one
operation for margins
7 27 )46 to 7
If cancer comes back in the breast after lumpectomy, it is
usually treated with mastectomy
29 27 )31 to 34
If 100 women have mastectomy, 2–10 will have cancer come
back in 10 years
21 13 )19 to 36
Radiation involves treatment 5 days a week for 5–6 weeks 21 13 )36 to 19
Side effects of radiation include fatigue and cosmetic
changes to the breast
7 13 )16 to 28
Breast reconstruction is an option that can be done at the
time of the mastectomy or later
29 7 )5 to 49
Most women are very satisfied with the way their breast
looks after lumpectomy
14 0 )33 to 4
Serious problems caused by radiation are rare 7 0 )6 to 21
Surgery goal*
Minimize the chance of cancer coming back in the treated
breast
100 93 )21 to 6
Be able to say you did everything possible 64 79 )19 to 47
Keep the breast 7 71 )92 to )37
Avoid side effects and complications of radiation therapy 0 21 )43 to 0
Do what your doctors think is best 86 14 )97 to )46
Remove the entire breast to gain peace of mind 14 14 )26 to 26
Avoid the hassle of radiation therapy 0 7 )21 to 6
Avoid breast reconstruction 14 0 )4 to 33
Bold print denotes statistically significant difference, P < 0.05.
CI, confidence interval.
*Shortened from the original wording.
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the success of the reconstruction than patients
(60% vs. 24%, 95% CI of the difference: )64,
)8). There was a trend towards greater patient
interest in the fact that patient satisfaction is
the same whether reconstruction is carried out
immediately or delayed (24% vs. 5%, 95% CI
of the difference: )2, 39). Patients also tended
to place more importance than providers did
on understanding that the data on complica-
tions is limited (24% vs. 5%, 95% CI of the
difference: )2, 39).
Reconstruction goals
The two most frequently selected goals were the
same for patients and providers: minimize the
number of operations and look natural in
clothes. Patients placed greater importance on
avoiding a prosthesis (33% vs. 0%, 95% CI of
the difference: 13, 54). There was a trend
towards less patient concern about looking
natural without clothes compared to providers
(24% vs. 40%, 95% CI of the difference: )12,
44).







95% CI of the
difference
Reconstruction fact*
Radiation can increase complications and affect cosmetic
result of reconstruction
24 60 )64 to )8
About one-third will have a major complication in the 2
years after reconstruction
67 40 )56 to 3
Reconstruction often requires multiple procedures over
multiple visits to complete
33 35 )27 to 31
Reconstruction can be at the time of mastectomy or delayed
for months or years
43 35 )22 to 38
Women who do not have reconstruction generally as
satisfied as women who do
5 30 )47 to )3
Women who have flap are more satisfied with the look and
feel than women who have implant
29 30 )26 to 29
Immediate reconstruction offers more natural look and feel
than delayed
38 30 )21 to 37
Implants require less extensive surgery than flaps 5 10 )21 to 11
Women who delay reconstruction are as satisfied as women
who have immediate
24 5 )2 to 39
Prosthesis can provide a natural look in clothes 10 5 )11 to 20
The data available to provide estimates of complications for
reconstruction is limited
23 5 )2 to 39
Reconstruction goal*
Look natural in clothes 43 60 )13 to 47
Minimize the number of surgeries 71 60 )40 to 18
Minimize recovery time 19 45 )54 to 2
Look natural without clothes 23 40 )12 to 44
Avoid a lengthy process 38 30 )21 to 37
Use your own tissue to create a breast 43 30 )16 to 42
Do what your doctor(s) think is best 24 15 )15 to 33
Do what your spouse thinks is best 5 10 )21 to 11
Avoid using a prosthesis 33 0 13 to 54
Bold print denotes statistically significant difference, P < 0.05.
CI, confidence interval.
*Shortened from the original wording.
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CHT facts
For both patients and providers, the best choice
depends on medical factors and patients feelings
about benefits and side effects and realistic
estimate of recurrence with chemotherapy or
hormone therapy were two of the three facts
most frequently selected (Table 3c). Although
24% of patients felt that chemotherapy can
cause rare but serious side effects was critical,
none of the providers selected that in their top
three (95% CI of the difference: 3, 44). None of
the providers selected any of the four items that
covered common and serious side effects of
chemotherapy and hormone therapy in their top
Table 3c Chemotherapy and hormone therapy: percentage of patients and providers who ranked each fact and goal in their
top 3







95% CI of the
difference
Best choice depends on medical factors and patients
feelings about benefits and side effects
41 52 )20 to 43
Realistic estimate of the risk of recurrence with CHT 41 48 )38 to 25
Chemotherapy can reduce recurrence and improve survival 12 38 )52 to 0
HT can reduce recurrence, improve survival in women with
hormone receptor positive tumours
12 33 )47 to 4
Size of the benefit from CHT depends on size of the risk of
recurrence
29 33 )26 to 34
Realistic estimate of the prognosis, recurrence, or death
without CHT
18 33 )43 to 11
60–75% will be cancer free 10 years after surgery without
CHT
29 29 )28 to 30
CHT reduces recurrence more than it increases survival 6 14 )27 to 10
Realistic estimate of how much CHT would help lengthen life 29 14 )42 to 11
Women with serious health problems may gain less benefit
from CHT
35 5 6 to 55
CH can cause short term, temporary side effects (nausea,
vomiting, hair loss, fatigue)
12 0 )4 to 27
CH can cause rare, serious side effects (heart problems,
cancers, infection, clots)
24 0 3 to 44
HT can cause temporary side effects (hot flashes, vaginal
discharge, sexual problems)
6 0 )5 to 17
HT can cause rare, serious side effects (blood clots,
endometrial cancer, bone loss)
6 0 )5 to 17







95% CI of the
difference
Live as long as possible 59 96 12 to 62
Reduce the chance that the cancer will come back 82 91 )13 to 30
Avoid serious side effects of chemotherapy 29 41 )41 to 18
Be able to say that you did everything possible 35 41 )25 to 36
Avoid serious side effects of hormone therapy 25 9 )4 to 45
Do what your doctor(s) think is best 6 9 )20 to 13
Avoid short-term side effects of chemotherapy 0 5 )13 to 4
Avoid lengthy treatment 24 5 )3 to 41
Maintain fertility 6 5 )13 to 16
Avoid short-term side effects of hormone therapy 12 0 )4 to 27
Bold print denotes statistically significant difference, P < 0.05.
CI, confidence interval; CHT, chemotherapy and ⁄ or hormone therapy; CH, chemotherapy; HT, hormone therapy.
*Shortened from the original wording.
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three, whereas 6–24% of patients put them in
their top three. Providers were more likely to put
benefits in their top three compared to patients
(for benefits of chemotherapy: 38% vs. 12%,
95% CI of the difference: )52, 1; for benefits of
hormone therapy: 33% vs. 12%, 95% CI of the
difference: )47, 4).
CHT goals
Patients and providers ranked the goals simi-
larly, although the emphasis was slightly differ-
ent. Significantly more providers felt that live as
long as possible was the main goal for CHT
decisions (95% vs. 59%, 95% CI of the differ-
ence: 12, 62). There was a trend towards patients
being more concerned than providers about
short-term side effects (12% vs. 0%, 95% CI of
the difference: )4, 27) and serious side effects
(25% vs. 9%, 95% CI of the difference: )41, 18)
of hormone therapy and about the length of
treatment (24% vs. 5%, 95% CI of the differ-
ence: )3, 41).
Discussion
Our approach to identifying the key facts and
goals for three breast cancer treatment decisions
is a significant step forward in the measurement
of the quality of these decisions and of prefer-
ence-sensitive decisions in general. The system-
atic process we used to identify the salient facts
and goals resulted in three sets of items that were
accurate, important and complete. In addition,
we observed several interesting differences in the
perspectives of patients and providers regarding
which facts and goals were most important.
Item development
Previous measures of decision making about
breast cancer treatments have been limited by
lack of validation7–12 or involvement of provid-
ers only in their development.6,9 The DQIs fol-
low a consensus-based framework that engages
patients and providers in generating items,25 is
based on principles of survey development31 and
is guided by decision theory25,32
In this first phase of instrument development,
we identified three sets of facts and goals. The
facts for all three decisions were accurate, with a
few clarifying comments added. The importance
of the facts and goals was also high, with only
CHT having items to delete. Although provider
and patient participants wrote in several sug-
gested additions, most were already covered by
the existing items or were not relevant to
selecting among treatments. These robust find-
ings confirm the validity of the item-generation
process for breast cancer decisions, a process
that has also been validated for symptom-driven
conditions.32
Significant variability existed within the
patient and provider groups, as well as between
the groups in prioritizing the facts and goals. In
fact, every fact and goal was selected in the top
three by at least one patient or provider, yet no
item was placed in the top three by 100% of
patients and providers. The closest was the sur-
gery goal, minimize the chance of having cancer
come back in the breast, which was placed in the
top three by 100% of patients and 92% of
providers. Despite this variability, we did iden-
tify a core set of facts and goals that met criteria
for importance, as rated by patients and pro-
viders.
How to handle goals considered highly
important by only a few participants is a chal-
lenge in the development of DQIs. We were able
to identify a set of goals that most patients felt
were important, but some goals were ranked in
the top three by only one or two patients. DQIs
should be broad enough to accommodate vari-
ation in a population, change over time and
differences among populations, but at the same
time, they cannot measure every possible goal
that patients may have. At this stage of devel-
opment, we erred on the side of inclusion and
deleted an item only if its weighted median
importance rating was <2 (somewhat impor-
tant), and if fewer than 10% of patients and
10% of providers ranked it in their top three.
We also asked patients to add any items they
felt were missing, which resulted in no addi-
tions.
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A strength of our approach to item develop-
ment has been the inclusion of patients per-
spectives at each step. Our finding of differences
between patients and providers rankings of the
facts and goals affirms the importance of
including both perspectives in item generation
and item reduction. The differences in rankings
may have implications for the development of
decision aids as well. Our findings affirm the
importance of including input from patients
early on in decision aid development, as they
bring a unique perspective to the process.
Significant limitations to our approach
include limited precision and the potential for
bias due to small, non-random samples. We used
convenience samples drawn from and around
academic institutions. Patients tended to be
white and well-educated, most patients in the
reconstruction sample had undergone recon-
struction and all of the patients in the CHT
sample were younger than 65 with some college
education. Less than half of the providers in the
surgery sample were surgeons. Whether or not
the issues and emphasis would be the same with
a more representative sample of patients is
unclear. However, a more diverse sample would
probably not yield increased consensus, so we
believe that the main insights regarding item
development would likely hold. The sample sizes
were large enough to examine the content
validity of the items, but not for the purpose of
drawing conclusions about patient or provider
opinion more generally. The samples were also
too small to test for associations between a
patients ranking of the goals and her treatment
choice. In the next phase of instrument devel-
opment, we will test instruments in larger, more
diverse populations.
Patient and provider perspectives on facts and
goals
Providers tended to be more uniform in their
opinions about the relative importance of the
facts and goals, while patients ratings showed
more diversity across items. For example, for the
CHT goals, 95% of providers placed live
as long as possible in the top three, 91% of
providers placed minimize recurrence in the top
three and almost no providers placed avoid
lengthy treatment, maintain fertility or avoid
short-term side effects of chemotherapy in the
top three. Providers homogeneity, in terms of
medical education and training, may account for
some of this uniformity, although other factors
not accounted for here may have also contrib-
uted. The finding that the patient sample had
more variability in their opinions affirms the
value of including patients in the processes of
item generation and item reduction.
We were surprised by the relative lack
of importance patients assigned to the goal of
keeping ones breast. Seven percentage of
patients ranked this item as a top three goal, and
women who had breast conservation were no
more likely to do so. In a recent study that used
an early version of the surgery DQI, women who
felt strongly about keeping their breast were
more than five times as likely to choose breast
conservation.27 Similarly, cross-sectional studies
of breast cancer patients have found that fear of
cancer, fear of recurrence, concern about losing
a breast, cosmetic result and body image were
associated with the choice of surgery.13,14,16,17,33
In the next phase of investigation, when we
validate the DQIs in large samples, we will have
a better understanding of the importance of this
goal.
Another somewhat surprising finding was the
difference in importance patients placed on
doing what the doctors think is best about sur-
gery, compared to providers. We have found this
discrepancy in other conditions, with patients
placing more emphasis on the provider than the
providers did.26 In contrast, patients considered
this less important for the other decisions, with
24% placing it in the top three for reconstruction
and 6% placing it in the top three for CHT. In a
recent population-based survey, many survivors
reported playing a small role in the decision
about surgery, and women who played a greater
role were more likely to have had a mastec-
tomy.9,34 Since the publication of guidelines
favouring breast conservation,35 surgeons may
be more likely to recommend breast conservation
without eliciting patients preferences.36
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Given the technical nature of surgery, one
might expect patients to defer decisions about
surgery to the surgeon, but we did not see the
same result for reconstruction. This discrepancy
may reflect a general absence of discussions
between patients and providers about recon-
struction.37,38 Alternatively, patients may see the
reconstruction decision as more personal than
the surgery decision. Ultimately, we believe that
doing what doctors think is best is a preference
about participation in decisions, and not a fun-
damental goal, so we have moved this item to a
section on participation in decisions, in subse-
quent versions of the DQIs.
With regard to reconstruction, patients
appeared to place more importance on practical
matters than providers did. A third of patients
placed avoid using a prosthesis in the top three
concerns, whereas not a single provider did.
More providers (40%) than patients (24%)
ranked the goal of looking natural without
clothing in the top three, although this difference
was not statistically significant. More providers
(60%) than patients (25%) ranked radiation can
affect the outcome of reconstruction in the top
three. Patients may be less concerned about the
effects of radiation on appearance of the recon-
structed breast. Alternatively, patients may have
ranked this fact highly only if they had had
radiation, whereas providers would have been
more aware of growing indications for post-
mastectomy radiation.39 How a patient feels
about body image is associated with breast
reconstruction,8 but we believe that patients may
value reconstruction as a means of returning to
their normal lives without having to worry
about the clothes they wear or whether they look
unbalanced or asymmetric. In general, patients
may have less concern than providers think they
do about how the reconstructed breast looks
without clothing.
Conclusion
This part of the survey development process is
replicable and generated accurate, important,
and complete sets of facts and goals for each of
three breast cancer treatment decisions. Because
patients and providers differ in what they see as
most important to these decisions, including
patients in the process of identifying the key
facts and goals is critical to the instrument
development process.
Survey instruments that can reliably examine
knowledge and patients preferences for different
attributes of treatment are important. As
guidelines and performance metrics increasingly
emphasize shared decision making and the
importance of informed patients, having ade-
quate measures to determine the extent to which
we can achieve those goals will be equally
important.
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